The 200 patients on the trial improved the time they were in therapeutic range from 60% of the time to 75% which reduces the risk of complications.
For the 200 participants in the study, their duration within the therapeutic range increased from 60% to 75%, which consequently decreased the likelihood of adverse outcomes.